GlassScriptPhysician profile
Julia Caouette
NPI 1801502323
$2,762.30
in general payments reported to CMS, 2019-2025
24 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $834 · 2024: $753 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.23 | 2023-2025 | |
| Glaxosmithkline, LLC. | $511.00 | 2023-2025 | Trelegy Ellipta, Penmenvy, Arexvy |
| Gilead Sciences, INC. | $192.90 | 2023-2025 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.31 | 2023-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $159.77 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $125.50 | 2023-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $117.18 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $100.52 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $84.71 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $81.80 | 2025 | Fanapt |
| Pfizer INC. | $75.97 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.08 | 2023-2024 | Jardiance |
| Corcept Therapeutics | $50.67 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $45.61 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $41.21 | 2023-2024 | Mounjaro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $33.87 | 2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $30.86 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $24.79 | 2024 | |
| Optinose US, INC. | $24.47 | 2024 | |
| Alkermes, INC. | $22.63 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $18.12 | 2025 | Rexulti |
| Verona Pharma, INC. | $17.86 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $17.46 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2024 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Caouette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.